SARS-CoV-2 Spike Protein (CR3022) Human IgG1 Monoclonal Antibody#37475,Cell Signaling Technology (CST),37475

SARS-CoV-2 Spike Protein (CR3022) Human IgG1 Monoclonal Antibody recognizes an epitope in the receptor binding domains (RBDs) of SARS-CoV-2 and SARS-CoV spike proteins. This antibody has been reported to bind to both wild-type and P462L-mutant versions of the SARS spike protein. The epitope is only accessible in the "open" conformation of the spike protein (10,11).

Host

Human

Reactivity

Virus

Platform ID

BAB131381258

Cell Signaling Technology (CST)

Headquarters

3 Trask Lane Danvers, MA 01923

Contact

Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355

Product Specifications
Scientific Background
Synonyms

Specifications

NameSARS-CoV-2 Spike Protein (CR3022) Human IgG1 Monoclonal Antibody#37475
Cat. No.37475
Accession NumberP0DTC2, 437405
Gene ID (Entrez)43740568
HostHuman
SensitivityRecombinant
ReactivityVirus
ImmunogenIgG1
StorageSupplied in PBS solution (pH 7.2). Store at –20°C. Avoid repeated freeze-thaw cycles.
Regulatory StatusResearch Use Only

Scientific Background

The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses (1). The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein (2). Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail (3,4). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2’ sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (2,4). In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (5-7). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (8,9).Zhou, P. et al. (2020)Nature579, 270-3.Tortorici, M.A. and Veesler, D. (2019)Adv Virus Res105, 93-116.Li, F. et al. (2006)J Virol80, 6794-800.Li, F. (2016)Annu Rev Virol3, 237-61.Shang, J. et al. (2020)Nature581, 221-4.Wrapp, D. et al. (2020)Science367, 1260-3.Yan, R. et al. (2020)Science367, 1444-8.Yuan, Y. et al. (2017)Nat Commun8, 15092.Amanat, F. and Krammer, F. (2020)Immunity52, 583-9.ter Meulen, J. et al. (2006)PLoS Med3, e237.Tian, X. et al. (2020)Emerg Microbes Infect9, 382-5.van den Brink, E.N. et al. (2005)J Virol79, 1635-44.Alternate Names2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein

Synonyms

2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.